Hematopoietic Stem Cell Therapies
Hematological disorders (e.g., post-transplant expansion)
Pre-clinicalActive
Key Facts
Indication
Hematological disorders (e.g., post-transplant expansion)
Phase
Pre-clinical
Status
Active
Company
About Plasticell
Plasticell is a private biotechnology company pioneering a high-throughput combinatorial screening platform, CombiCult®, to rapidly develop optimized cell culture protocols for regenerative medicine. Its therapeutic pipeline is centered on advanced cell and gene therapies, including iPSC-derived allogeneic cancer immunotherapies, hematopoietic stem cell expansion, and treatments for thrombocytopenia and anemia. The company operates through a collaborative business model, partnering with academic and industry leaders like Imperial College London and the Cell and Gene Therapy Catapult to advance its programs and manufacturing capabilities.
View full company profile